A Day Up For Cassava Sciences, Inc.
Cassava Sciences, Inc. (SAVA:NASDAQ) jumped higher at $9.65, representing a gain of 34%. On Thu 02 Jan 20, SAVA:NASDAQ touched a New 2-Week High of $7.2. The stock got featured on our News Catalysts scanner on Thu 02 Jan 20 at 11:55 AM in the 'RECOMMENDATION' category. From Wed 11 Dec 19, the stock recorded 57.14% Up Days and 46.67% Green Days
About Cassava Sciences, Inc. (SAVA:NASDAQ)
Pain Therapeutics Inc is a biopharmaceutical company. It develops proprietary drugs that offer improvements to patients and healthcare professionals. The company generally focuses on the drug development efforts on disorders of the nervous system, such as chronic pain. Pain Therapeutics operates in the single operating segment. Pain Therapeutics's drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The company's other product includes FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use.
Top 10 Gainers:
- Leap Therapeutics, Inc. (LPTX:NASDAQ), 52.61%
- Guardion Health Sciences, Inc. (GHSI:NASDAQ), 42.8%
- Lilis Energy, Inc. (LLEX:NASDAQ), 39.73%
- Lilis Energy, Inc. (LLEX:NYSEMKT), 39.73%
- Inpixon (INPX:NASDAQ), 38.3%
- Cassava Sciences, Inc. (SAVA:NASDAQ), 34.03%
- NanoViricides, Inc. (NNVC:NYSEMKT), 32.81%
- Yuma Energy, Inc. (YUMA:NYSEMKT), 28.66%
- Pacific Coast Oil Trust (ROYT:NYSE), 27.27%
- Nymox Pharmaceutical Corporation (NYMX:NASDAQ), 26.61%